Brought to you by 
Ambit Biosciences gets $25mm in first tranche of Series E financing
08 Nov 2012
Executive Summary
Ambit Biosciences Inc. (developing small-molecule kinase inhibitors for cancer) raised $25mm through the first tranche of its $50mm Series E round. All existing investors participated, including OrbiMed Advisors (which led and takes a seat on the company's board), Aisling Capital, Apposite Healthcare, Roche Venture Fund, GrowthWorks, MedImmune Ventures, Forward Ventures, GIMV, and Radius Ventures. Proceeds will go towards the company's lead candidate quizartinib (AC220), an FMS-like tyrosine kinase-3 inhibitor that is in Phase II trials (with partner Astellas Pharma) for relapsed or refractory acute myeloid leukemia and treatment-naive AML.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ambit Biosciences gets $25mm in first tranche of Series E financing
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice